Giapreza Patent Expiration

Giapreza is a drug owned by La Jolla Pharma Llc. It is protected by 11 US drug patents filed from 2018 to 2023 out of which none have expired yet. Giapreza's patents have been open to challenges since 21 December, 2021. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 06, 2037. Details of Giapreza's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11219662 Methods for treating hypotension in a patient that has received an ACE inhibitor by administering angiotensin II
Jan, 2037

(12 years from now)

Active
US11559559 Angiotensin II alone or in combination for the treatment of hypotension
Dec, 2034

(10 years from now)

Active
US11096983 Angiotensin II alone or in combination for the treatment of hypotension
Dec, 2034

(10 years from now)

Active
US10028995 Angiotensin II alone or in combination for the treatment of hypotension
Dec, 2034

(10 years from now)

Active
US10493124 Angiotensin II alone or in combination for the treatment of hypotension
Dec, 2034

(10 years from now)

Active
US9220745 Angiotensin II alone or in combination for the treatment of hypotension
Dec, 2034

(10 years from now)

Active
US9572856 Method of treating low blood pressure
Nov, 2030

(5 years from now)

Active
US9867863 Method of treating low blood pressure
Dec, 2029

(5 years from now)

Active
US10335451 Method of treating low blood pressure
Dec, 2029

(5 years from now)

Active
US10548943 Method of treating low blood pressure
Dec, 2029

(5 years from now)

Active
US10500247 Method of treating low blood pressure
Dec, 2029

(5 years from now)

Active


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Giapreza's patents.

Given below is the list of recent legal activities going on the following patents of Giapreza.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 4th Year, Large Entity 04 Aug, 2023 US10548943
Payment of Maintenance Fee, 8th Year, Large Entity 29 Jun, 2023 US9220745
Payment of Maintenance Fee, 4th Year, Large Entity 12 Jun, 2023 US10500247
Payment of Maintenance Fee, 4th Year, Large Entity 05 Jun, 2023 US10493124
Sequence Moved to Public Database 24 Jan, 2023 US11559559
Recordation of Patent Grant Mailed 24 Jan, 2023 US11559559
Patent Issue Date Used in PTA Calculation 24 Jan, 2023 US11559559
Email Notification 05 Jan, 2023 US11559559
Issue Notification Mailed 04 Jan, 2023 US11559559
Payment of Maintenance Fee, 4th Year, Large Entity 03 Jan, 2023 US10335451


FDA has granted several exclusivities to Giapreza. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Giapreza, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Giapreza.

Exclusivity Information

Giapreza holds 1 exclusivities. All of its exclusivities have expired in 2022. Details of Giapreza's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 21, 2022

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Giapreza is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Giapreza's family patents as well as insights into ongoing legal events on those patents.

Giapreza's Family Patents

Giapreza has patent protection in a total of 23 countries. It's US patent count contributes only to 37.7% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click below to unlock the full patent family tree for Giapreza.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Giapreza's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jan 06, 2037 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Giapreza Generics:

There are no approved generic versions for Giapreza as of now.

How can I launch a generic of Giapreza before its drug patent expiration? :

You can seek FDA approval to launch a generic drug before the expiration of Giapreza's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Giapreza's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Given below are the details of the already filed Para IV certificates on Giapreza -

Strength Submission Date ANDA(s) Filed First applicant approval Last patent expiry 180 day status
2.5 mg/mL 21 Dec, 2021 1 18 Dec, 2034





About Giapreza

Giapreza is a drug owned by La Jolla Pharma Llc. It is used for increasing blood pressure and treating shock, especially in patients unresponsive to other vasopressors. Giapreza uses Angiotensin Ii Acetate as an active ingredient. Giapreza was launched by La Jolla Pharma in 2021.

Approval Date:

Giapreza was approved by FDA for market use on 23 December, 2021.

NCE-1 date:

NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Giapreza is 23 December, 2021, its NCE-1 date is estimated to be 21 December, 2021.

Active Ingredient:

Giapreza uses Angiotensin Ii Acetate as the active ingredient. Check out other Drugs and Companies using Angiotensin Ii Acetate ingredient

Treatment:

Giapreza is used for increasing blood pressure and treating shock, especially in patients unresponsive to other vasopressors.

Dosage:

Giapreza is available in solution form for intravenous use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML) SOLUTION Prescription INTRAVENOUS
EQ 5MG BASE/2ML (EQ 2.5MG BASE/ML) SOLUTION Discontinued INTRAVENOUS
EQ 0.5MG BASE/ML (EQ 0.5MG BASE/ML) SOLUTION Prescription INTRAVENOUS